---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-26-000101"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2026-09-16T20:05:40+00:00"
generated_at: "2026-09-16T20:07:31.841812+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio appoints Greg Ciongoli to board, Audit Committee

## Summary
- Ciongoli, Class III director effective Sept 16, 2026, term to 2027 annual meeting; joins Audit Committee.
- Founder/managing partner of Adiumentum Capital (since 2024); ex-Baupost Group partner; also on REGENXBIO, Zymeworks, Atara boards.
- He participated in Aug 2026 PIPE: pre-funded warrants for ~22,337 common (initial), ~111,687 (second closing), ~66,845 (FDA approval) post-approval.
- Annual cash retainers: $40,000 board, $7,500 audit; standard equity award amount set at future board discretion.

## SEC filing metadata
- accession: 0001728117-26-000101
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2026-09-16T20:05:40+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000101/0001728117-26-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000101/goss-20260916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-26-000101
- JSON: https://secwatch.observer/filing/0001728117-26-000101.json
- Plain text: https://secwatch.observer/filing/0001728117-26-000101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.